News Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Market Closed - Nyse Other stock markets 04:00:02 2024-04-23 pm EDT			After market 04:58:43 pm
48.99 ^USD	-0.31%		48.94	-0.11%

11:29am	Novartis Nominates Former Bristol Myers Squibb CEO as New Chair	MT
11:12am	Novartis Lifts 2024 Guidance as First-quarter Earnings Grow on Strong Blockbuster Drug Demand	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Novartis Nominates Former Bristol Myers Squibb CEO as New Chair	05:29am	MT
Novartis Lifts 2024 Guidance as First-quarter Earnings Grow on Strong Blockbuster Drug Demand	05:12am	MT
Novartis raises targets for 2024	03:21am	CF
Alexandria Real Estate's Q1 FFO rises on stronger occupancy rates	Apr. 22	RE
Bristol-Myers Squibb Signs $380 Million Deal With Cellares to Manufacture CAR T Cell Therapies	Apr. 22	MT
Bristol Myers signs $380 mln CAR-T therapies supply deal with Cellares	Apr. 22	RE
Bristol Myers signs supply agreement with Cellares	Apr. 22	CF
Bristol Myers Squibb and Cellares reach $380 mln supply deal for CAR-T therapies	Apr. 22	RE
Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster	Apr. 22	BU
Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster	Apr. 22	BU
Bristol Myers Squibb and Cellares Announce Worldwide Capacity Reservation and Supply Agreement for Manufacture of CAR T Cell Therapies	Apr. 22	CI
Cantor Fitzgerald Adjusts Bristol-Myers Squibb's Price Target to $52 From $55, Maintains Neutral Rating	Apr. 22	MT
US FDA mandates label updates on CAR-T cancer therapies	Apr. 18	RE
Wells Fargo Adjusts Bristol-Myers Squibb's Price Target to $52 From $51, Keeps Equalweight Rating	Apr. 18	MT
Pathios Therapeutics Limited announced a financing transaction	Apr. 17	CI
Actinium Pharmaceuticals (ATNM) Garners Attention with Clinical Successes and Strategic Market Moves Amid Growing Radiopharma Interest	Apr. 17	AQ
TORL BioTherapeutics LLC announced that it has received $158.3 million in funding from a group of investors	Apr. 16	CI
Asher Biotherapeutics, Inc. announced that it has received $55 million in funding from a group of investors	Apr. 15	CI
Wolfe Research Adjusts Price Target on Bristol-Myers Squibb Company to $55 From $57, Outperform Rating Kept	Apr. 15	MT
Wolfe Research Adjusts Price Target on Bristol-Myers Squibb to $55 From $57, Maintains Outperform Rating	Apr. 15	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 01:06 pm EST